{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T00:23:10Z","timestamp":1793751790103,"version":"4.6.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"DOI":"10.1007\/s40618-025-02712-3","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T14:41:04Z","timestamp":1759156864000},"page":"425-433","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Multi-database pharmacovigilance assessment of GLP-1 receptor agonist-related ophthalmic risks using advanced signal detection in FAERS and vigibase"],"prefix":"10.1007","volume":"49","author":[{"given":"Xiao","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziwei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangyao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Furong","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"issue":"1","key":"2712_CR1","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s12933-020-01154-w","volume":"19","author":"G Schernthaner","year":"2020","unstructured":"Schernthaner G, Shehadeh N, Ametov AS, Bazarova AV, Ebrahimi F, Fasching P, Jane\u017e A, Kempler P, Konr\u0101de I, Lali\u0107 NM, Mankovsky B, Martinka E, Raheli\u0107 D, Serafinceanu C, \u0160krha J, Tankova T, Visockien\u0117 \u017d (2020) Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes. Cardiovasc Diabetol 19(1):185","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"2712_CR2","doi-asserted-by":"publisher","first-page":"106951","DOI":"10.1016\/j.medcli.2025.106951","volume":"165","author":"H Sard\u00e0","year":"2025","unstructured":"Sard\u00e0 H, Genua I, Mi\u00f1ambres I (2025) GLP-1 receptor agonists in obesity treatment: effects on cardiometabolic variables and cardiovascular disease. Med Clin (Barc) 165(1):106951 English, Spanish","journal-title":"Med Clin (Barc)"},{"key":"2712_CR3","doi-asserted-by":"crossref","unstructured":"Lakhani M, Kwan AT, Mihalache A, Popovic MM, Nanji K, Xie JS, Feo A, Rabinovitch D, Shor R, Sadda S, Sarraf D, Hurley B, Margolin EA, Kertes PJ, Chaudhary V, Muni RH Association of Glucagon-like Peptide-1 Receptor Agonists with Optic Nerve and Retinal Adverse Events: A Population-Based Observational Study Across 180 Countries. Am J Ophthalmol. 2025 May 16:S0002-9394(25)00239-9","DOI":"10.1016\/j.ajo.2025.05.007"},{"issue":"4","key":"2712_CR4","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1001\/jamaophthalmol.2024.6555","volume":"143","author":"CX Cai","year":"2025","unstructured":"Cai CX, Hribar M, Baxter S, Goetz K, Swaminathan SS, Flowers A, Brown EN, Toy B, Xu B, Chen J, Chen A, Wang S, Lee C, Leng T, Ehrlich JR, Barkmeier A, Armbrust KR, Boland MV, Dorr D, Boyce D, Alshammari T, Swerdel J, Suchard MA, Schuemie M, Bu F, Sena AG, Hripcsak G, Nishimura A, Nagy P, Falconer T, DuVall SL, Matheny M, Viernes B, O\u2019Brien W, Zhang L, Martin B, Westlund E, Mathioudakis N, Fan R, Wilcox A, Lai A, Stocking JC, Takkouche S, Lee LH, Xie Y, Humes I, McCoy DB, Adibuzzaman M, Areaux RG Jr, Rojas-Carabali W, Brash J, Lee DA, Weiskopf NG, Mawn L, Agrawal R, Morgan-Cooper H, Desai P, Ryan PB (2025) Semaglutide and nonarteritic anterior ischemic optic neuropathy. JAMA Ophthalmol 143(4):304\u2013314","journal-title":"JAMA Ophthalmol"},{"issue":"3","key":"2712_CR5","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1001\/jamaophthalmol.2024.6058","volume":"143","author":"BJ Katz","year":"2025","unstructured":"Katz BJ, Lee MS, Lincoff NS, Abel AS, Chowdhary S, Ellis BD, Najafi A, Nguyen J, Seay MD, Warner JEA (2025) Ophthalmic complications associated with the antidiabetic drugs semaglutide and Tirzepatide. JAMA Ophthalmol 143(3):215\u2013220","journal-title":"JAMA Ophthalmol"},{"key":"2712_CR6","doi-asserted-by":"publisher","first-page":"e076410","DOI":"10.1136\/bmj-2023-076410","volume":"384","author":"H Yao","year":"2024","unstructured":"Yao H, Zhang A, Li D, Wu Y, Wang CZ, Wan JY, Yuan CS (2024) Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ 384:e076410","journal-title":"BMJ"},{"issue":"1","key":"2712_CR7","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1146\/annurev-pharmtox-061324-011832","volume":"65","author":"Q Zhou","year":"2025","unstructured":"Zhou Q, Li G, Hang K, Li J, Yang D, Wang MW (2025) Weight loss blockbuster development: a role for unimolecular polypharmacology. Annu Rev Pharmacol Toxicol 65(1):191\u2013213","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"2712_CR8","doi-asserted-by":"publisher","first-page":"231","DOI":"10.2337\/dc15-0165","volume":"39","author":"MA Nauck","year":"2016","unstructured":"Nauck MA, Petrie JR, Sesti G, Mannucci E, Courr\u00e8ges JP, Lindegaard ML, Jensen CB, Atkin SL (2016) A phase 2, randomized, dose-finding study of the novel once-weekly human GLP-1 analog, semaglutide, compared with placebo and open-label liraglutide in patients with type 2 diabetes. Diabetes Care 39:231\u2013241","journal-title":"Diabetes Care"},{"key":"2712_CR9","volume-title":"National diabetes statistics Report, 2022","author":"Centers for Disease Control and Prevention (CDC)","year":"2022","unstructured":"Centers for Disease Control and Prevention (CDC) (2022) National diabetes statistics Report, 2022. CDC, Atlanta, GA"},{"issue":"6 Suppl","key":"2712_CR10","doi-asserted-by":"publisher","first-page":"S114","DOI":"10.1097\/MLR.0b013e3181dbebe3","volume":"48","author":"MA Brookhart","year":"2010","unstructured":"Brookhart MA, St\u00fcrmer T, Glynn RJ, Rassen J, Schneeweiss S (2010) Confounding control in healthcare database research: challenges and potential approaches. Med Care 48(6 Suppl):S114\u2013S120","journal-title":"Med Care"},{"issue":"10","key":"2712_CR11","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1016\/j.ophtha.2008.08.023","volume":"115","author":"R Klein","year":"2008","unstructured":"Klein R, Klein BE, Moss SE (2008) The Wisconsin epidemiologic study of diabetic retinopathy: XVII. the 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology 115(10):1859\u20131868","journal-title":"Ophthalmology"},{"issue":"3","key":"2712_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12030454","volume":"12","author":"E Rentzeperi","year":"2022","unstructured":"Rentzeperi E, Pegiou S, Koufakis T, Grammatiki M, Kotsa K (2022) Sex differences in response to treatment with Glucagon-like peptide 1 receptor agonists: opportunities for a tailored approach to diabetes and obesity care. J Pers Med 12(3):454","journal-title":"J Pers Med"},{"key":"2712_CR13","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13293-016-0059-9","volume":"7","author":"JE Richard","year":"2016","unstructured":"Richard JE, Anderberg RH, L\u00f3pez-Ferreras L, Olandersson K, Skibicka KP (2016) Sex and estrogens alter the action of glucagon-like peptide-1 on reward. Biol Sex Differ 7:6","journal-title":"Biol Sex Differ"},{"key":"2712_CR14","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.coph.2021.06.007","volume":"60","author":"I Campesi","year":"2021","unstructured":"Campesi I, Seghieri G, Franconi F (2021) Type 2 diabetic women are not small type 2 diabetic men: sex-and-gender differences in antidiabetic drugs. Curr Opin Pharmacol 60:40\u201345","journal-title":"Curr Opin Pharmacol"},{"issue":"8","key":"2712_CR15","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1001\/jamaophthalmol.2024.2514","volume":"142","author":"SP Mollan","year":"2024","unstructured":"Mollan SP (2024) Semaglutide and nonarteritic anterior ischemic optic neuropathy. JAMA Ophthalmol 142(8):740\u2013741","journal-title":"JAMA Ophthalmol"},{"issue":"12","key":"2712_CR16","first-page":"1373","volume":"42","author":"JL Montastruc","year":"2019","unstructured":"Montastruc JL, Bondon-Guitton E, Abadie D et al (2019) Pharmacovigilance, Risks, and adverse effects: focus on methodological challenges in international databases. Drug Saf 42(12):1373\u20131385","journal-title":"Drug Saf"},{"issue":"3","key":"2712_CR17","first-page":"295","volume":"44","author":"K Plueschke","year":"2021","unstructured":"Plueschke K, McGettigan P, Pacurariu A et al (2021) Regional differences in spontaneous adverse drug reaction reporting: A comparative analysis of the WHO vigibase and the U.S. FAERS. Drug Saf 44(3):295\u2013306","journal-title":"Drug Saf"},{"issue":"6","key":"2712_CR18","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","volume":"18","author":"A Bate","year":"2009","unstructured":"Bate A, Evans SJW (2009) Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf 18(6):427\u2013436","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"14","key":"2712_CR19","first-page":"1643","volume":"75","author":"EC Davies","year":"2015","unstructured":"Davies EC, Chandler RE, de Vries ST et al (2015) Lixisenatide: A review of its use in the management of type 2 diabetes mellitus. Drugs 75(14):1643\u20131658","journal-title":"Drugs"},{"issue":"8","key":"2712_CR20","first-page":"e123","volume":"45","author":"YR Chung","year":"2022","unstructured":"Chung YR, Park SW, Choi SY et al (2022) Association of GLP-1 receptor agonists with diabetic retinopathy: A pharmacovigilance study. Diabetes Care 45(8):e123\u2013e125","journal-title":"Diabetes Care"},{"issue":"4","key":"2712_CR21","first-page":"890","volume":"108","author":"J Zhou","year":"2023","unstructured":"Zhou J, Wang X, Zhang S (2023) Long-term use of GLP-1 receptor agonists and risk of cataract formation: a meta-analysis. J Clin Endocrinol Metab 108(4):890\u2013898","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2712_CR22","first-page":"45","volume":"14","author":"J Nguyen","year":"2025","unstructured":"Nguyen J, Chowdhary S, Warner JEA et al (2025) Ischemic optic neuropathy following GLP-1 receptor agonist therapy: A case series and literature review. Ophthalmol Ther 14(1):45\u201358","journal-title":"Ophthalmol Ther"},{"issue":"6","key":"2712_CR23","first-page":"1123","volume":"71","author":"R Sim\u00f3","year":"2022","unstructured":"Sim\u00f3 R, Hern\u00e1ndez C (2022) GLP-1 receptor agonists and neurovascular protection in diabetic retinopathy: mechanistic insights and therapeutic potential. Diabetes 71(6):1123\u20131135","journal-title":"Diabetes"},{"issue":"6","key":"2712_CR24","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1007\/s13300-025-01728-5","volume":"16","author":"B Osumili","year":"2025","unstructured":"Osumili B, Sapin H, Yang Z, Ranta K, Paik JS, Bl\u00fcher M (2025) Efficacy and safety of Tirzepatide compared with GLP-1 RAs in patients with type 2 diabetes treated with basal insulin: a network meta-analysis. Diabetes Ther 16(6):1279\u20131311","journal-title":"Diabetes Ther"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-025-02712-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-025-02712-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-025-02712-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T05:19:31Z","timestamp":1771651171000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-025-02712-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":24,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["2712"],"URL":"https:\/\/doi.org\/10.1007\/s40618-025-02712-3","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]},"assertion":[{"value":"8 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}